MULTIPLE MYELOMA

Based on data from the phase II ELOQUENT-3 trial, elotuzumab (Empliciti) has received approval from the FDA in combination with pomalidomide (Pomalyst) and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.

Eric Smith, MD, PhD, discusses the use of armored chimeric antigen receptor T cells in multiple myeloma.

Newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem cell transplant saw a 45% reduction in the risk of disease progression or death with the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone compared with lenalidomide/dexamethasone alone.

Eric Smith, MD, PhD, discusses challenges with CAR T-cell therapy as a treatment option for multiple myeloma. While studies have shown CD19 CAR T cells and BCMA CAR T cells have durable responses in this patient population, patients still relapse over time.

A new drug application for selinexor has been granted a priority review by the FDA as a treatment for patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics, the manufacturer of the agent.

Infographic: Here, we share the top 5 oncology news stories we reported this week, including the most recent FDA updates and expert insights on key developments in the field.

The next-generation sequencing assay clonoSEQ has gained FDA approval as a test for minimal residual disease in patients with acute lymphoblastic leukemia or multiple myeloma.

A once-weekly dosing option&nbsp;of carfilzomib (Kyprolis) has been approved by the FDA for use&nbsp;in combination with dexamethasone for patients with relapsed/refractory multiple myeloma, Amgen, the manufacturer of the agent, has announced.<br /> &nbsp;

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, for patients with relapsed/refractory multiple myeloma, as well as emerging immunotherapy treatment options.